ANN ARBOR, MI -- (MARKET WIRE) -- April 30, 2007 -- Pipex Pharmaceuticals, Inc. (OTCBB: PPEX) (“Pipex”), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it presented two oral presentations at the Annual Wilson’s Disease Association (WDA) Conference in New York on April 28th. The presentations entitled “Tetrathiomolybdate for Neurological Initial Presenting Wilson’s Disease - an Industry Drug Development Perspective” and “Direct Measurement of Free and Bound Copper with a New Electrochemical Device - FreeBound” were presented by Steve H. Kanzer, Chairman and Chief Executive Officer of Pipex.
